IFITM5

Summary

IFITM5 (interferon induced transmembrane protein 5, HGNC:16644) is a protein-coding gene on chromosome 11p15.5, encoding Interferon-induced transmembrane protein 5 (A6NNB3). Required for normal bone mineralization.

This gene encodes a membrane protein thought to play a role in bone mineralization. This gene is located on chromosome 11 in a cluster of related genes which are induced by interferon, however, this gene has not been shown to be interferon inducible. A similar gene, located in a gene cluster on mouse chromosome 7, is a member of the interferon-inducible fragilis gene family. The mouse gene encodes a transmembrane protein described as participating in germ cell competence. A mutation in the 5’ UTR of this gene has been associated with osteogenesis imperfecta type V (PMID: 22863190, 22863195).

Source: NCBI Gene 387733 — RefSeq curated summary.

At a glance

• Gene–disease (curated): osteogenesis imperfecta type 5 (Definitive, GenCC)
• GWAS associations: 3
• Clinical variants (ClinVar): 181 total — 2 pathogenic
• Phenotypes (HPO): 20
• MANE Select transcript: NM_001025295

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16644
Approved symbol	IFITM5
Name	interferon induced transmembrane protein 5
Location	11p15.5
Locus type	gene with protein product
Status	Approved
Aliases	fragilis4, Hrmp1, BRIL, DSPA1
Ensembl gene	ENSG00000206013
Ensembl biotype	protein_coding
OMIM	614757
Entrez	387733

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000382614

RefSeq mRNA: 1 — MANE Select: NM_001025295 NM_001025295

CCDS: CCDS31323

Canonical transcript exons

ENST00000382614 — 2 exons

Exon	Start	End
ENSE00001492770	298200	298713
ENSE00001492773	299305	299526

Expression profiles

Bgee: expression breadth broad, 83 present calls, max score 76.19.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 17.9365 / max 1920.3394, expressed in 63 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
117735	17.9365	63

Top tissues by expression

111 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
body of pancreas	UBERON:0001150	76.19	gold quality
granulocyte	CL:0000094	61.46	gold quality
blood	UBERON:0000178	59.68	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	59.45	gold quality
pancreas	UBERON:0001264	59.33	gold quality
bone marrow cell	CL:0002092	55.49	gold quality
bone marrow	UBERON:0002371	52.26	gold quality
mucosa of stomach	UBERON:0001199	51.34	gold quality
right lung	UBERON:0002167	50.85	gold quality
right coronary artery	UBERON:0001625	49.28	gold quality
upper lobe of left lung	UBERON:0008952	48.10	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	48.06	gold quality
small intestine Peyer’s patch	UBERON:0003454	45.55	gold quality
lung	UBERON:0002048	45.23	gold quality
right lobe of liver	UBERON:0001114	45.16	gold quality
small intestine	UBERON:0002108	44.85	gold quality
metanephros cortex	UBERON:0010533	43.73	gold quality
descending thoracic aorta	UBERON:0002345	43.67	gold quality
colonic epithelium	UBERON:0000397	42.27	gold quality
liver	UBERON:0002107	42.01	gold quality
thyroid gland	UBERON:0002046	42.00	gold quality
spleen	UBERON:0002106	41.29	gold quality
thoracic mammary gland	UBERON:0005200	40.95	gold quality
duodenum	UBERON:0002114	40.82	gold quality
right lobe of thyroid gland	UBERON:0001119	40.78	gold quality
mucosa of transverse colon	UBERON:0004991	40.78	silver quality
stromal cell of endometrium	CL:0002255	40.67	silver quality
left lobe of thyroid gland	UBERON:0001120	40.61	gold quality
tonsil	UBERON:0002372	40.53	gold quality
subcutaneous adipose tissue	UBERON:0002190	39.04	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-CURD-112	yes	17.09
E-ANND-3	no	0.37

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GLI2, SP1, SP3, SP7

miRNA regulators (miRDB)

12 targeting IFITM5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-486-3P	99.51	66.82	1901
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-4641	99.28	66.64	744
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-1911-3P	99.15	66.17	528
HSA-MIR-4758-3P	99.12	63.96	869
HSA-MIR-4763-3P	99.10	67.83	2649
HSA-MIR-296-5P	97.61	64.02	851
HSA-MIR-122-5P	97.23	64.92	1024
HSA-MIR-874-5P	96.93	63.92	1014
HSA-MIR-4772-5P	95.60	68.04	617

Literature-anchored findings (GeneRIF, showing 12)

• A single recurrent mutation in the 5’-UTR of IFITM5 causes osteogenesis imperfecta type V. (PMID:22863190)
• A mutation in the 5’-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. (PMID:22863195)
• study demonstrates the presence of a recurrent IFITM5 mutation in a population of patients with osteogenesis imperfecta type V; even though the disease-causing mutation is identical among patients, the interindividual phenotypic variability is considerable (PMID:23240094)
• The bone mineral density varied greatly, even within families. Our study thus highlights the phenotypic variability of OI type V caused by the IFITM5 mutation. (PMID:23408678)
• IFITM5 mutation is associated with Osteogenesis imperfecta type V. (PMID:23804581)
• Recurrent mutation in the 5’-UTR of IFITM5 causes osteogenesis imperfecta type V. (PMID:23813632)
• The point mutation, c.-14C>T in the 5’-untranslated region of IFITM5, is responsible for osteogenesis imperfecta type V in Chinese patients. (PMID:23977282)
• Two mutations in IFITM5 causing distinct forms of osteogenesis imperfect. (PMID:24478195)
• The IFITM5 5’ UTR was sequenced in 9 heterozygous subjects with osteogenesis imperfecta type V. Both wild-type and mutant IFITM5 mRNA transcripts were present in bone. Identical mutations have variable phenotypic expression, even within the same family. (PMID:24674092)
• We suggest that all patients negative for COL1A1/2 pathogenic variants be tested for the presence of an IFITM5 pathogenic variant, even if they are not expressing typical osteogenesis imperfecta V symptoms. (PMID:31159867)
• Coalescing expansile skeletal disease: Delineation of an extraordinary osteopathy involving the IFITM5 mutation of osteogenesis imperfecta type V. (PMID:33360005)
• The Osteogenesis Imperfecta Type V Mutant BRIL/IFITM5 Promotes Transcriptional Activation of MEF2, NFATc, and NR4A in Osteoblasts. (PMID:35216266)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ifitm5	ENSDARG00000105153
mus_musculus	Ifitm5	ENSMUSG00000025489
rattus_norvegicus	Ifitm5	ENSRNOG00000014923

Paralogs (5): IFITM3 (ENSG00000142089), IFITM2 (ENSG00000185201), IFITM1 (ENSG00000185885), IFITM10 (ENSG00000244242), (ENSG00000300510)

Protein

Protein identifiers

Interferon-induced transmembrane protein 5 — A6NNB3 (reviewed: A6NNB3)

Alternative names: Bone-restricted interferon-induced transmembrane protein-like protein, Dispanin subfamily A member 1

All UniProt accessions (1): A6NNB3

UniProt curated annotations — full annotation on UniProt →

Function. Required for normal bone mineralization.

Subunit / interactions. Interacts with FKBP11.

Subcellular location. Cell membrane.

Tissue specificity. Detected in osteoblasts and fibroblasts (at protein level). Detected in bone.

Post-translational modifications. Palmitoylated.

Disease relevance. Osteogenesis imperfecta 5 (OI5) [MIM:610967] An autosomal dominant form of osteogenesis imperfecta, a disorder of bone formation characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Disease severity ranges from very mild forms without fractures to intrauterine fractures and perinatal lethality. Extraskeletal manifestations, which affect a variable number of patients, are dentinogenesis imperfecta, hearing loss, and blue sclerae. OI5 patients manifest moderate to severe bone fragility, calcification of the forearm interosseous membrane, radial head dislocation, a subphyseal metaphyseal radiodense line, and hyperplastic callus formation. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the CD225/Dispanin family.

RefSeq proteins (1): NP_001020466* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007593	CD225/Dispanin_fam	Family
IPR051517	IFITM_antiviral_protein	Family

Pfam: PF04505

UniProt features (13 total): topological domain 3, lipid moiety-binding region 3, sequence variant 2, transmembrane region 2, chain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-A6NNB3-F1	65.49	0.07

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 84, 50, 51

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 100 (showing top): GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOBP_ANIMAL_ORGAN_MORPHOGENESIS, GOBP_BONE_DEVELOPMENT, GOBP_IN_UTERO_EMBRYONIC_DEVELOPMENT, GOBP_RESPONSE_TO_KETONE, GOBP_BONE_MINERALIZATION, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_OSSIFICATION, GOBP_EMBRYO_DEVELOPMENT, GOBP_BONE_MORPHOGENESIS, GOBP_RESPONSE_TO_ETHER, GOBP_RESPONSE_TO_ALCOHOL, GOBP_SKELETAL_SYSTEM_MORPHOGENESIS

GO Biological Process (7): in utero embryonic development (GO:0001701), bone mineralization (GO:0030282), regulation of bone mineralization (GO:0030500), bone morphogenesis (GO:0060349), response to tacrolimus (GO:1901327), response to rapamycin (GO:1901355), skeletal system development (GO:0001501)

GO Molecular Function (0):

GO Cellular Component (3): cytosol (GO:0005829), plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
response to nitrogen compound	2
cellular anatomical structure	2
chordate embryonic development	1
ossification	1
biomineral tissue development	1
regulation of ossification	1
bone mineralization	1
regulation of biomineral tissue development	1
animal organ morphogenesis	1
skeletal system morphogenesis	1
bone development	1
response to oxygen-containing compound	1
response to ether	1
response to alcohol	1
response to ketone	1
system development	1
cytoplasm	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

824 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IFITM5	CRTAP	O75718	783
IFITM5	TMEM38B	Q9NVV0	776
IFITM5	FKBP10	Q96AY3	735
IFITM5	P3H1	Q32P28	722
IFITM5	SERPINF1	P36955	677
IFITM5	PLOD2	O00469	630
IFITM5	BMP1	P13497	630
IFITM5	SEC24D	O94855	629
IFITM5	CREB3L1	Q96BA8	628
IFITM5	COL1A2	P02464	626
IFITM5	ADORA2A	P29274	623
IFITM5	SERPINH1	P29043	621
IFITM5	PLS3	P13797	610
IFITM5	MBTPS2	O43462	605
IFITM5	COL1A1	P02452	603

IntAct

5 interactions, top by confidence:

A	B	Type	Score
	IFITM5	psi-mi:“MI:0915”(physical association)	0.560
IFITM5	APOB	psi-mi:“MI:0914”(association)	0.350
IFITM5		psi-mi:“MI:0915”(physical association)	0.000

BioGRID (6): IFITM5 (Two-hybrid), APOB (Affinity Capture-MS), XPO7 (Affinity Capture-MS), IKBIP (Affinity Capture-MS), PKD2 (Affinity Capture-MS), ATXN3 (Affinity Capture-MS)

ESM2 similar proteins: A0A087WTH1, A2RRL7, A5D7M7, A6NNB3, C9JQL5, K7EJ46, O70491, O88728, P0C5X8, P13164, P26376, P70606, Q01628, Q01629, Q0V8E7, Q1HG43, Q1HG44, Q1KZG0, Q2KJ98, Q2MHH0, Q2TA35, Q49LS7, Q4QR83, Q4VV71, Q5M8E3, Q5R7B4, Q5RCC0, Q5T197, Q5T1A1, Q640M6, Q6PEY1, Q6ZNR0, Q7TNJ2, Q7YQI4, Q8BH02, Q8C581, Q8IUH8, Q8IXB3, Q8IZY2, Q8WTR4

Diamond homologs: A6NMD0, A6NNB3, C9JQL5, O88728, P13164, P26376, Q01628, Q01629, Q8BR26, Q91499, Q99J93, Q9CQW9, Q9D103, D3ZFB6, E9PUL5, Q2MHH0, Q5RAC1, Q6DFT4, Q7Z6L0, Q8C838

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
GLI2	“up-regulates quantity by expression”	IFITM5	“transcriptional regulation”
SP1	“up-regulates quantity by expression”	IFITM5	“transcriptional regulation”
SP7	“up-regulates quantity by expression”	IFITM5	“transcriptional regulation”
SP3	“up-regulates quantity by expression”	IFITM5	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

181 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	71
Likely benign	50
Benign	27

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
183677	NM_001025295.3(IFITM5):c.119C>T (p.Ser40Leu)	Pathogenic
37143	NM_001025295.3(IFITM5):c.-14C>T	Pathogenic

SpliceAI

143 predictions. Top by Δscore:

Variant	Effect	Δscore
11:298710:GGGC:G	acceptor_gain	1.0000
11:298714:C:CC	acceptor_gain	1.0000
11:299302:CACCT:C	donor_loss	1.0000
11:299303:ACCTT:A	donor_loss	1.0000
11:299304:C:CA	donor_loss	1.0000
11:298709:CGGGC:C	acceptor_gain	0.9900
11:298711:GGC:G	acceptor_gain	0.9900
11:298712:GC:G	acceptor_gain	0.9900
11:298713:CC:C	acceptor_gain	0.9900
11:298713:CCT:C	acceptor_loss	0.9900
11:298714:C:CA	acceptor_loss	0.9900
11:298715:T:C	acceptor_loss	0.9900
11:298717:C:CT	acceptor_gain	0.9900
11:298714:C:T	acceptor_gain	0.9800
11:298726:C:T	acceptor_gain	0.9700
11:299303:A:AC	donor_gain	0.9700
11:299304:C:CC	donor_gain	0.9700
11:298726:C:CT	acceptor_gain	0.9600
11:298727:A:T	acceptor_gain	0.9600
11:298711:GGCCT:G	acceptor_gain	0.9500
11:298712:GCCTG:G	acceptor_gain	0.9500
11:298713:CCTGC:C	acceptor_gain	0.9500
11:298710:GGGCC:G	acceptor_gain	0.9300
11:298714:C:A	acceptor_gain	0.9300
11:298718:A:T	acceptor_gain	0.9200
11:298715:T:G	acceptor_gain	0.9100
11:298731:C:CT	acceptor_gain	0.8500
11:299438:G:A	donor_gain	0.8400
11:299372:G:T	donor_gain	0.8300
11:299364:TGAA:T	donor_gain	0.8200

AlphaMissense

834 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:299312:G:A	S60F	0.984
11:299362:G:C	S43R	0.984
11:299362:G:T	S43R	0.984
11:299364:T:G	S43R	0.984
11:298642:G:C	N86K	0.983
11:298642:G:T	N86K	0.983
11:298626:A:G	W92R	0.979
11:298626:A:T	W92R	0.979
11:299305:C:A	K62N	0.972
11:299305:C:G	K62N	0.972
11:299334:C:G	G53R	0.970
11:299312:G:T	S60Y	0.968
11:299347:A:C	N48K	0.968
11:299347:A:T	N48K	0.968
11:299324:G:T	A56E	0.965
11:298596:C:G	G102R	0.964
11:298596:C:T	G102R	0.964
11:298706:T:A	D65V	0.961
11:299333:C:T	G53D	0.959
11:298709:C:G	R64P	0.958
11:298580:C:T	G107D	0.957
11:299340:A:G	C51R	0.957
11:298676:G:T	A75D	0.956
11:298656:C:G	A82P	0.954
11:299376:A:G	W39R	0.953
11:299376:A:T	W39R	0.953
11:298706:T:G	D65A	0.951
11:298707:C:G	D65H	0.948
11:299313:A:G	S60P	0.947
11:298604:A:C	L99R	0.946

dbSNP variants (sampled 300 via entrez): RS1000533804 (11:299978 C>T), RS1000543749 (11:300155 G>A,C,T), RS1001784042 (11:300892 G>A), RS1002522169 (11:298329 G>A,C,T), RS1003214590 (11:300048 G>A,C), RS1003581198 (11:297762 C>A), RS1003601554 (11:301505 A>G), RS1004936171 (11:298702 C>A,G,T), RS1005340568 (11:301517 G>A), RS1005498186 (11:297865 C>T), RS1005539092 (11:297929 G>A,T), RS1006343462 (11:300579 G>A), RS1006363950 (11:298932 C>A,T), RS1006650448 (11:301317 C>T), RS1008364604 (11:300415 C>T)

Disease associations

OMIM: gene MIM:614757 | disease phenotypes: MIM:166200, MIM:610967

GenCC curated gene-disease

Disease	Classification	Inheritance
osteogenesis imperfecta type 5	Definitive	Autosomal dominant

Mondo (3): osteogenesis imperfecta (MONDO:0019019), osteogenesis imperfecta type 5 (MONDO:0012591), postmenopausal osteoporosis (MONDO:0008159)

Orphanet (2): Osteogenesis imperfecta (Orphanet:666), Osteogenesis imperfecta type 5 (Orphanet:216828)

HPO phenotypes

20 total (20 of 20 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000325	Triangular face
HP:0000592	Blue sclerae
HP:0000703	Dentinogenesis imperfecta
HP:0000926	Platyspondyly
HP:0000938	Osteopenia
HP:0001187	Hyperextensibility of the finger joints
HP:0001382	Joint hypermobility
HP:0001763	Pes planus
HP:0002644	Abnormal pelvic girdle bone morphology
HP:0002645	Wormian bones
HP:0002757	Recurrent fractures
HP:0003593	Infantile onset
HP:0004322	Short stature
HP:0004586	Biconcave vertebral bodies
HP:0005084	Anterior radial head dislocation
HP:0006394	Limited pronation/supination of forearm
HP:0008422	Vertebral wedging
HP:0010485	Hyperextensibility at elbow
HP:0030268	Hyperplastic callus formation

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST011353_8	Serum alkaline phosphatase levels	7.000000e-39
GCST011365_141	Myocardial infarction	7.000000e-06
GCST90011900_65	Serum alkaline phosphatase levels	1.000000e-71

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004533	alkaline phosphatase measurement

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D010013	Osteogenesis Imperfecta	C05.116.099.708.685; C16.320.737; C17.300.200.540
D015663	Osteoporosis, Postmenopausal	C05.116.198.579.610; C18.452.104.579.610
C567042	Osteogenesis Imperfecta, Type V (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

7 total (human), top 7 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases methylation	2
aflatoxin B2	decreases methylation	1
Resveratrol	affects cotreatment, decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Cyclosporine	decreases methylation	1
Aflatoxin B1	decreases methylation	1

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E1ZT	HAP1 IFITM5 (-) 1	Cancer cell line	Male
CVCL_E1ZU	HAP1 IFITM5 (-) 2	Cancer cell line	Male
CVCL_E1ZV	HAP1 IFITM5 (-) 3	Cancer cell line	Male
CVCL_E1ZW	HAP1 IFITM5 (-) 4	Cancer cell line	Male

Clinical trials (associated diseases)

197 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00131469	PHASE4	COMPLETED	Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta
NCT00159419	PHASE4	COMPLETED	Bisphosphonate Therapy for Osteogenesis Imperfecta
NCT01713231	PHASE4	COMPLETED	Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta
NCT02303873	PHASE4	COMPLETED	Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta
NCT03735537	PHASE4	COMPLETED	Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
NCT04152551	PHASE4	RECRUITING	Effects of Bisphosphonates on OI-Related Hearing Loss
NCT00079924	PHASE4	COMPLETED	Effects of Teriparatide in Postmenopausal Women With Osteoporosis
NCT00239629	PHASE4	COMPLETED	Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial
NCT00545051	PHASE4	COMPLETED	A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.
NCT00545363	PHASE4	COMPLETED	A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)
NCT00545909	PHASE4	COMPLETED	BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis
NCT00729651	PHASE4	COMPLETED	Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)
NCT01544894	PHASE4	COMPLETED	Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis
NCT01709110	PHASE4	COMPLETED	VERtebral Fracture Treatment Comparisons in Osteoporotic Women
NCT01750086	PHASE4	COMPLETED	Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
NCT02176382	PHASE4	COMPLETED	Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
NCT02499237	PHASE4	COMPLETED	Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation
NCT02598440	PHASE4	COMPLETED	A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
NCT02598453	PHASE4	COMPLETED	PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia
NCT02604836	PHASE4	COMPLETED	A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
NCT03472846	PHASE4	COMPLETED	MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis
NCT04026256	PHASE4	COMPLETED	Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
NCT04719481	PHASE4	UNKNOWN	Pravastatin Reduces Acute Phase Response of Zoledronic Acid
NCT04719650	PHASE4	UNKNOWN	Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid
NCT05010590	PHASE4	ACTIVE_NOT_RECRUITING	Anabolic Therapy in Postmenopausal Osteoporosis
NCT05630768	PHASE4	COMPLETED	Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
NCT05645289	PHASE4	UNKNOWN	Efficacy and Safety of Minodronate in Patients With Low Back Pain
NCT05902078	PHASE4	RECRUITING	Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis
NCT06079476	PHASE4	COMPLETED	A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
NCT06767150	PHASE4	RECRUITING	StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis
NCT06938152	PHASE4	RECRUITING	Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients
NCT07406685	PHASE4	NOT_YET_RECRUITING	The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation
NCT00001305	PHASE3	COMPLETED	Growth Hormone Therapy in Osteogenesis Imperfecta
NCT00005901	PHASE3	COMPLETED	Pamidronate to Treat Osteogenesis Imperfecta in Children
NCT00106028	PHASE3	COMPLETED	Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children
NCT00982124	PHASE3	COMPLETED	An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta
NCT02352753	PHASE3	TERMINATED	Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI
NCT03638128	PHASE3	TERMINATED	Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta
NCT05768854	PHASE3	ACTIVE_NOT_RECRUITING	Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta
NCT05972551	PHASE3	ACTIVE_NOT_RECRUITING	Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta